04:43 AM EST, 12/09/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.

Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.

The data also showed the inducement of "robust, durable production of fetal hemoglobin," the company said.

Beam Therapeutics ( BEAM ) said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.

BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.